NEWS 2020 | Appili Therapeutics
May 21, 2020
Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks
May 11, 2020
Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities
May 4, 2020
Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference
April 21, 2020
Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer
February 27, 2020
Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020 Copy
February 20, 2020
Appili Therapeutics Announces Closing of Public Offering of $10,250,000
February 14, 2020
Appili Therapeutics Announces Upsizing of Previously Announced Equity Offering
February 13, 2020
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
February 12, 2020
Appili Therapeutics Announces Overnight Marketed Equity Offering
January 28, 2020
Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats
January 27, 2020
Appili Therapeutics Appoints Veteran Biotech Executive Dr. Juergen Froehlich to Its Board of Directors
January 7, 2020
Appili Celebrates a Notable 2019 and Looks Ahead to Significant Milestones in 2020